{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024500","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.026860+00:00","generated_at":"2026-06-15T00:38:28.474174+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics Q1 net loss widens to $11.5M; NAVIGATE trial fully enrolled with 357 patients","bullets":["Net loss of $11.5M ($0.19/shr) vs $9.9M loss in Q1 2022, driven by higher R&D costs.","R&D expenses rose to $8.8M from $8.1M, primarily for the NAVIGATE trial.","Cash and equivalents $17.8M; additional $40M available under chairman's line of credit.","NAVIGATE Phase 2b/3 trial for NASH cirrhosis esophageal varices enrolled 357 patients; interim results expected Q4 2024.","Company evaluating potential Phase 2 trial of belapectin + Keytruda in advanced head and neck cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024500","json":"https://secwatch.observer/filing/0001140361-23-024500.json","markdown":"https://secwatch.observer/filing/0001140361-23-024500.md","text":"https://secwatch.observer/filing/0001140361-23-024500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/0001140361-23-024500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/brhc20052846_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:38:28.474174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"454fd818f67904f69ff52ba3b0561aee07f85f75","claim":"GALECTIN THERAPEUTICS INC reported three months ended March 31, 2023 results: net income net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, EPS ($0.19) per share.","evidence_excerpt":"Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/0001140361-23-024500-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"net loss applicable to common stockholders of $11.5 million, or ($0.19) per share"},{"label":"EPS","value":"($0.19) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}